Minirin (Desmopressin Acetate)

Desmopressin acetate mimics the natural hormone vasopressin and selectively activates V2 receptors in the kidney’s collecting ducts. This triggers a cascade that inserts aquaporin‑2 channels into the cell membrane, allowing more water to be reabsorbed, concentrating urine and reducing urine volume. In bleeding disorders, it also promotes release of clotting factors from endothelial cells.

The dose of Minirin is individualized by the prescribing clinician based on the specific indication, patient age, weight, renal function, and response to therapy. Dosage adjustments may be required during treatment initiation, when electrolyte levels change, or if the patient experiences side effects. Patients should follow the prescriber’s instructions and not alter the dose on their own.

Safety data for desmopressin acetate in pregnancy and lactation are limited. The drug should only be used when the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers will assess the individual situation, and women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their physician.

To request Minirin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and assistance with import documentation.

Minirin (desmopressin) is a synthetic vasopressin analogue that offers greater selectivity for V2 receptors, resulting in a longer duration of action and fewer vasoconstrictive effects compared with natural vasopressin. Unlike some other antidiuretic agents, it can be administered sublingually and is also approved for haemostatic use, providing a dual therapeutic profile.

Minirin should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging to protect it from moisture and light. Do not store in a bathroom or near a heat source, and keep it out of reach of children.

Minirin is supplied as a sublingual tablet. The tablet is placed under the tongue and allowed to dissolve completely without chewing or drinking water. Administration should occur on an empty stomach, typically at least 30 minutes before or after meals, to ensure consistent absorption.

The most serious risks include severe hyponatremia, which can lead to seizures, cerebral edema, or even death, and water intoxication from excessive fluid retention. Patients should be monitored for sudden changes in weight, headache, confusion, or vomiting, and serum sodium levels should be checked regularly during therapy.

Minirin is contraindicated in individuals with known hypersensitivity to desmopressin or any excipients, in patients with uncontrolled hyponatremia, and in those with severe renal impairment where water clearance is compromised. Caution is also advised for patients with a history of hyponatremic seizures, pulmonary edema, or uncontrolled hypertension.